Revolution Medicines (NASDAQ:RVMD) Insider Alan Sandler Sells 6,309 Shares of Stock

Key Points

• Insider sale: Alan Sandler sold 6,309 Revolution Medicines shares for approximately $1.28 million at an average price of $202.14, reducing his position by 10.72% to 52,559 shares.
• Stock and earnings: RVMD recently traded at $205.89, near its 52-week high, but the company reported a quarterly loss of $3.06 per share, missing analysts’ estimate of a $2.04 loss.
• Analyst sentiment: Wall Street maintains a “Moderate Buy” consensus, with an average price target of $234.33; institutional investors own 94.34% of the company’s stock.

Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) insider Alan Sandler sold 6,309 shares of the business's stock in a transaction that occurred on Tuesday, September 29th. The shares were sold at an average price of $202.14, for a total value of $1,275,301.26. Following the completion of the sale, the insider owned 52,559 shares in the company, valued at $10,624,276.26. The trade was a 10.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Revolution Medicines Stock Up 0.3%

NASDAQ:RVMD traded up $0.63 during trading hours on Thursday, reaching $205.89. 1,710,457 shares of the stock were exchanged, compared to its average volume of 2,893,928. The stock has a market cap of $44.13 billion, a PE ratio of -23.34 and a beta of 1.40. Revolution Medicines, Inc. has a twelve month low of $45.60 and a twelve month high of $224.31. The firm has a 50 day moving average of $202.11 and a 200 day moving average of $165.61. The company has a debt-to-equity ratio of 0.40, a current ratio of 11.38 and a quick ratio of 11.38.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($3.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.04) by ($1.02). During the same quarter in the prior year, the business posted ($1.31) EPS. On average, equities analysts expect that Revolution Medicines, Inc. will post -8.87 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on RVMD. Guggenheim lifted their price target on shares of Revolution Medicines from $240.00 to $275.00 and gave the company a "buy" rating in a research note on Friday, August 28th. TD Cowen upgraded shares of Revolution Medicines to a "strong-buy" rating in a research note on Monday, August 24th. UBS Group raised their price objective on Revolution Medicines from $220.00 to $265.00 and gave the company a "buy" rating in a report on Friday, August 28th. Brookline Capital Markets began coverage on Revolution Medicines in a research report on Monday. They issued a "buy" rating and a $318.00 target price on the stock. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Revolution Medicines in a report on Friday, July 17th. Two analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Revolution Medicines has an average rating of "Moderate Buy" and an average price target of $234.33.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Burkett Financial Services LLC bought a new stake in shares of Revolution Medicines in the 3rd quarter valued at about $27,000. Contravisory Investment Management Inc. bought a new position in Revolution Medicines during the second quarter worth about $32,000. Johnson Financial Group Inc. bought a new position in Revolution Medicines during the second quarter worth about $37,000. Silvant Capital Management LLC acquired a new position in Revolution Medicines during the second quarter worth approximately $41,000. Finally, Northwestern Mutual Wealth Management Co. acquired a new position in Revolution Medicines during the second quarter worth approximately $41,000. Institutional investors own 94.34% of the company's stock.

About Revolution Medicines

Revolution Medicines, Inc is a clinical-stage biotechnology company focused on developing targeted therapies for patients with cancer. The company's research centers on the RAS signaling pathway, a key driver of tumor growth that is altered in many cancers, including those involving KRAS mutations.

Its pipeline includes RAS(ON) inhibitors designed to target active RAS proteins and address a range of RAS-driven tumors. Key development programs include daraxonrasib (RMC-6236), a broad-spectrum RAS inhibitor, and zoldonrasib (RMC-9805), an investigational inhibitor aimed at KRAS G12D-mutated cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.